✦ LIBER ✦

Combined Pharmacodynamic and Transcriptome Profiling of Recombinant Human Interleukin-21 Responses in Patients with Stage IV Malignant Melanoma

✍ Scribed by Dorthe Lundsgaard; Klaus Stensgaard Frederiksen; Lasse Tengbjerg Hansen; Birte K. Skrumsager; Ulrik Mouritzen; Grant McArthur; Ian D. Davis; Kresten Skak

Book ID: 113539612
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 43 KB
Volume: 123
Category: Article
ISSN: 1090-2341
DOI: 10.1016/j.clim.2007.03.095

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OR.85. Leukocyte Responses during Recomb

OR.85. Leukocyte Responses during Recombinant Human Interleukin-21 Treatment of Patients with Stage IV Melanoma

✍ Kresten Skak; Klaus Stensgaard Frederiksen; Jenny Lau; Ulrik Mouritzen; Grant Mc 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 42 KB

408 POSTER Phase 1 study of recombinant

408 POSTER Phase 1 study of recombinant human Interleukin-21 (rIL-21) in combination with sunitinib in patients with stage IV renal cell carcinoma

✍ V. Grünwald; I. Desar; J. Haanen; W. Fiedler; M.B. Olsen; C.M.L. van Herpen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A phase I-II trial of the combination of

A phase I-II trial of the combination of recombinant leukocyte a interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

✍ Edward T. Creagan; Charles L. Loprinzi; David L. Ahmann; Daniel J. Schaid 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 2 views

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

A phase II study of combined administrat

A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-α2a in patients with advanced malignant melanoma

✍ Han G. Ron; Yair Mordish; Avi Eisenthal; Yehuda Skornick; Moshe J. Inbar; Samari 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 584 KB

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t